ClinicalTrials.gov
public full text
Public Domain
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that means at least 12 months more than the 18-20 months generally described.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)#866037
- Improving REsectability in Pancreatic NEoplasms (IRENE)#847637
- Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer#1009115
- Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer#1140637
- Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer#1150119
Record · ID 1086499
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive